Clinical parameters to evaluate the efficacy of allergen-specific immunotherapy in allergic rhinoconjunctivitis. Calculation of "well days" as an adjunct concept;Klinische parameter zur beurteilung der wirksamkeit einer spezifischen immuntherapie bei polleninduzierter rhinitis allergica. Bestimmung von "well days" als ergänzendes konzept

Allergologie

Volumn 33, Issue 1, 2010, Pages 35-42

  Vorwalder, Stefanie ^a   Pfaar, O ^a   Klimek, L ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

"well days"; Allergic rhinoconjunctivitis; Conjunctival provocation tests; Immunotherapy; Medication score; Nasal provocation tests; Skin prick tests; Symptom score

Indexed keywords

ALLERGEN; IMMUNOMODULATING AGENT; PLACEBO;

ALLERGIC RHINITIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; HUMAN; IMMUNOTHERAPY; PROVOCATION TEST; REVIEW; RHINOCONJUNCTIVITIS; SKIN TEST;

EID: 77649313243     PISSN: 03445062     EISSN: None     Source Type: Journal    
DOI: 10.5414/alp33035     Document Type: Review

References (63)

1. Albegger K. Diagnose der allergischen Rhinitis. I. Anamnese - HNO-ärztliche Untersuchung - Hautteste - Intranasale Provokation. HNO. 1991; 39: 77-81.
2. Bachert C. Untersuchungen zur Reproduzierbarkeit des intranasalen Provokationstests. Laryng Rhinol Otol. 1987; 66: 157-160.
3. Bachert C, Keilmann A. Zur Sensitivität und Spezifität der intranasalen Provokation. Laryng Rhinol Otol. 1988; 67: 57-60.
4. Bachmann W, Bachert C. Die nasale Provokation. In: Fuchs E, Schulz KH (eds). Manuale allergologicum. München - Orlando: Dustri; 1994.
5. Basomba A, Bousquet J, Dreborg S, Frew AJ, Haahtela T. Position Paper: Allergen standardization and skin tests. Allergy. 1993; 47: 48-82.
6. Blackley CH. Experimental researches on the causes and nature of catarrhus aestivus (hay fever or hay asthma). London: Dawsons of Pall Mall, Faksimile Druck; 1959.
7. Bousquet J, Bullinger M, Fayol C, Marquis P, Valentin B, Burtin B. Assessment of quality of life in patients with perennial allergic rhinitis with the French version of the SF-36 Health Status Questionnaire. J Allergy Clin Immunol. 1994; 94: 182-188.
8. Bousquet J, Lockey RF, Malling HJ. WHO Position Paper - Allergen immunotherapy: therapeutic vaccines for allergic diseases - Geneva, January 27 - 29, 1997. Allergy. 1998; 53: 4-42.
9. Bousquet J, Maasch HJ, Martinot B, Hejjaoui A, Wahl R, Michel FB. Doubleblind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. II. Comparison between parameters assessing the efficacy of immunotherapy. J Allergy Clin Immunol. 1988; 82: 439-446.
10. Carlsson AM. Assessment of chronic pain. I. Aspects of the reliability and validity of the visual analogue scale. Pain. 1983; 16: 87-101.
11. Hermann-Kunz E. Heuschnupfenprävalenz in Deutschland - Ost-West-Vergleich und zeitlicher Trend. Gesundheitswesen. 1999; 61: 94-99.
12. de Weck AL, Glück U, Derer T. Thermographic analysis of allergic reactions in the skin. ACI News. 1990; 211: 7-10.
13. Ding-E Young J, Peterson CGB, Venge P, Cohn ZA. Mechanism of membranedamage mediated by human eosinophil cationic protein. Nature. 1986; 321: 613-616.
14. Doyle WJ, Skoner DP, Seroky JT, Fireman P. Reproducibility of the effects of intranasal ragweed challenges in allergic subjects. Annals of Allergy, Asthma, and Immunology. 1995; 74: 171-176.
15. Dreborg S. The skin prick test. Methodological studies and clinical applications. 1-148. Linköping University Nr. 23; 1987.
16. Dreborg S, Backman A, Basomba A, Bousquet J, Dieges P, Malling HJ. Skin tests used in type 1 allergy testing. Position paper prepared by the Sub-Committee on Skin Tests of the European Academy of Allergology and Clinical Immunology. Allergy. 1989; 44 (Suppl 10): 1-59.
17. Durham SR, Varney V. Mechanisms. In: Kay AB (ed). Allergy and allergic diseases. Oxford - London: Blackwell Science; 1997, 1227-1233.
18. Durham SR, Ying S, Varney VA, Jacobson MR, Sudderick RM, Mackay IS, Kay AB, Hamid QA. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messengerRNAfor interferon-gamma. J Allergy Clin Immunol. 1996; 97: 1356-1365.
19. Fähndrich E, Linden M. Zur Reliabilität und Validität der Stimmungsmessung mit der Visuellen Analog-Skala (VAS). Pharmacopsychiatrics. 1982; 15: 90-94.
20. Fling JA, Ruff ME, ParkerWA, Whisman BA, Martin ME, Moss RB, Reid MJ. Suppression of the late cutaneous response by immunotherapy. J Allergy Clin Immunol. 1989; 83: 101-109.
21. Frati F, Incorvaia C, Marcucci F, Sensi L, Di Cara G, Puccinelli P, Da Bo S. Dose dependence of efficacy but not of safety in sublingual immunotherapy. Monaldi Arch Chest Dis. 2006; 65: 38-40.
22. Fuchs E, Gronemeyer W. Hautproben. In: Fuchs E, Schulz KH (eds). Manuale allergologicum. München - Orlando: Dustri; 1988.
23. Furin MJ, Norman PS, Creticos PS, Proud D, Kagey-Sobotka A, Lichtenstein LM, Naclerio RM. Immunotherapy decreases antigen-induced eosinophil migration into the nasal cavity. J Allergy Clin Immunol. 1991; 88: 27-32.
24. Gaston-Johansson F, Johansson G, Sanne H. A comparative study of pain description, emotional discomfort and health perception in patients with chronic pain syndrome and rheumatoid arthritis. Scand J Rehab Med. 1985; 17: 109-119.
25. Gonsior EC, Bachert C, Berdel D, Enzmann H, Fuchs E, Hofmann D, Keller H, Nitz U, Rudolph R, Rüdiger W, Schlenter WW. Richtlinien für die Durchführung von nasalen Provokationstests mit Allergenen bei Erkrankungen der oberen Luftwege. Arbeitskreis "Bronchiale und nasale Provokationstests" der Deutschen Gesellschaft für Allergie-und Immunitätsforschung. Allergologie. 1990; 13: 53-55.
26. Guidance for Industry. Allergic rhinitis: clinical development programs for drug products. Draft guidance. U.S. Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER); April 2000.
27. Guideline on the clinical development of products for specific immunotherapy. Committee for Medicinal Products of Human Use (CHMP); May 24, 2007.
28. Halpern SR, Holmann J, Whittaker C. The correlation between skin and respiratory mucous membrane tests with molds in allergic rhinitis. Ann Allergy. 1961; 19: 1407.
29. Heinisch M, Ludwig M, Bullinger M. Psychometrische Testung der Münchner Lebensqualitäts-Dimensionen-Liste (MLDL). In: Bullinger M, Ludwig M, von Steinbücherl N (eds). Lebensqualität bei kardiovaskulären Erkrankungen. Göttingen: Hogrefe; 1991, 73-90.
30. Huskisson EC. Measurement of pain. Lancet. 1974; 4: 1127-1131.
31. Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy. 1991; 21: 77-83.
32. Kleine-Tebbe J, Bergmann K-C, Friedrichs F, Fuchs T, Jung K, Klimek L, Kühr J, LässigW, Lepp U, Niggemann B, Rakoski J, RebienW, Renz H, Saloga J, Simon J, Sitter H, Virchow C,Worm M. Die spezifische Immuntherapie (Hyposensibilisierung) bei IgE-vermittelten allergischen Erkrankungen. Leitlinie der Deutschen Gesellschaft für Allergologie und klinische Immunologie (DGAKlinische KI), des Ärzteverbandes Deutscher Allergologen (ÄDA) und der Deutschen Gesellschaft für pädiatrische Allergologie und Umweltmedizin (GPA). Allergo J. 2006; 15: 56-74.
33. Klimek L, Weber K, Mann W. Der Hauttest-Scanner (STS). Allergologie. 1998; 21: 527-533.
34. Klimek L. Einfluss der Immuntherapie auf Symptomatik, Zellaktivierungsmarker und inflammatorische Mediatoren bei allergischer Rhinitis. Allergo J. 1997; 6: 158-160.
35. Klimek L, Mewes T. Hyposensibilisierungsbehandlung bei saisonaler allergischer Rhinitis: Kurzzeit- versus Langzeittherapie. Allergologie. 1996; 19: 432.
36. Knop J. Hauttests. In: Nolte H (ed). Allergie: Grundlage, Diagnostik, Therapie und Prophylaxe. München - Orlando: Dustri; 1992.
37. Kremer B, Klimek L, Bullinger M, Mösges R. Generic or disease-specific quality of life scales to characterize health status in allergic hinitis? Alrlergy. 2001; 56: 957-963.
38. Lenders H, Gall H. Die nasale Provokationstestung. Ein Vergleich zwischen anteriorer Rhinomanometrie und akustischer Rhinomanometrie. Allergologie. 1992; 7: 233-239.
39. Malling HJ. New ideas in allergen-specific immunotherapy. Am J Rhinol. 1990; 4: 155-158.
40. Malling HJ. Methods of skin testing. Position Paper: Allergen standardization and skin tests. EAACI Executive Committee. Allergy. 1993; 14 (Suppl): 55-56.
41. Malling HJ, Weeke B. Position Paper: Immunotherapy of the EAACI. Allergy. 1993; 48: 9-35 (and appendicies).
42. Malling HJ. Criteria for clinical efficacy: readout and monitoring of clinical studies. Frankfurt am Main: Arb Paul-Ehrlich-Institut, Bundesamt Sera Impfstoffe; 2003, 119-123.
43. Neumann Y, Bullinger M, Przybilla B. Quality of life in allergic rhinitis: standardisation of a self-assessment questionnaire. Allergy. 1992; 47 (Suppl 12): 72.
44. Nordic Council on Medicine. Registration of allergenic preparations. Nordic Guidelines, Vol 23; 2nd edition. Uppsala, Sweden: NLN Publications; 1989, 1-34.
45. Norman PS. Immunotherapy. In: Melillo G, Norman PS, Marone G (eds). Respiratory allergy. Toronto: BC Decker; 1990, 3-15.
46. Olson R, Karpink MH, Shelanski S, Atkins PC, Zweiman B. Skin reactivity to codeine and histamine during prolonged corticosteroid therapy. J Allergy Clin Immunol. 1990; 86: 153-159.
47. Petersen LJ, Bindslev-Jensen C, Poulsen LK, Malling HJ. Time of onset of action of acrivastine in the skin of pollen-allergic subjects. A doubleblind, randomized, placebo-controlled comparative study. Allergy. 1994; 49: 27-30.
48. Pipkorn U, Hammarlund A, Enerbäck L. Prolonged treatment with topical glucocorticosteroids results in an inhibition of the allergen-induced weal-and-flare response and a reduction in skin mast cell numbers and histamine content. Clin Exp Allergy. 1989; 19: 19-25.
49. Saumet JL, Dittmar A, Leftheriotis G. Non-invasive measurements of skin blood flow: comparison between plethysmography, laser-doppler flowmeter and heat thermography. Int J Microcirc Clin Exp. 1986; 5: 73-83.
50. Serup J, Staberg B. Quantification of weal reactions with laser doppler flowmetry. Allergy. 1985; 140: 233-237.
51. Simons FER, McMillan JL, Simons KJ. A double-blind, single dose, crossover comparison of cetirizine, terfenadine, loratadine, astemizol and chlorpheniramine versus placebo: suppressive effects on histamine-induced weals and flares during 24 hours in normal subjects. J Allergy Clin Immunol. 1990; 86: 540-547.
52. Staberg B, Serup J. Allergic and irritant skin reactions evaluated by laser doppler flowmetry. Contact Dermatitis. 1988; 18: 40-45.
53. Swain ID, Grant LJ. Methods of measuring skin blood flow. Phys Med Biol. 1989; 34: 171-175.
54. Tenland T. On laser doppler flowmetry. Medizinische Dissertation 1-162, Universität Linköping; 1982.
55. Turkeltaub PC. In vivo methods of measuring skin blood flow. Phys Med Biol. 1989; 4: 371.
56. Uematsu T, Takiguchi Y, Mizuno A, Sogabe K, Nakashima M. Application of thermography to the evaluation of the histamine skin test in man. J Pharmacol Methods. 1987; 18: 103-110.
57. Van Bever HP, Stevens WJ. Suppression of the late asthmatic reaction by hyposensitisation in asthmatic children allergic to house dust mite (Dermatophagoides pteronyssinus). Clin Exp Allergy. 1989; 19: 399-404.
58. Van Metre TE, Adkinson NF. Immunotherapy for aeroallergen disease. In: Reed CE, Ellis EF, Adkinson NF, Yunginger JW (ed). Allergy: principles and practice. St. Louis: CV Mosby; 1988, 1327-1343.
59. Varney V, Gaga M, Frew AJ, Aber VR, Kay AB, Durham SR. Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. Brit Med J. 1991; 302: 265-269.
60. Walker SM, Varney VA, Gaga M, Jacobson M, Durham SR. Grass pollen immunotherapy: efficacy and safety during a 4-year follow-up study. Allergy. 1995; 50: 405-413.
61. Warner JO, Soothill JF, Price JF, Hey EN. Controlled trial of hyposensitisation to Dermatophagoides pteronyssinus in children with asthma. Lancet. 1978; ii: 912-915.
62. Worm M. Efficacy and tolerability of high dose sublingual immunotherapy in patients with rhinoconjunctivitis. Eur Ann Allergy Clin Immunol. 2006; 38: 355-360.
63. Worm M. "Well days" after sublingual immunotherapy with a high-dose 6-grass pollen preparation. Allergy. 2009; 64: 1104-1105.